Key Dates

Related Announcements

PAR-22-114 - Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice informs the community of an application forms package issue with PAR-22-114 titled ‘Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)’.

The application forms package originally posted with this Funding Opportunity Announcement (FOA) was mistakenly posted as a multi-project package rather than a single-project package. To address this issue, the original application forms package needed to be deleted, and a new application forms package posted in Grants.gov. The new package can be identified by a Competition ID of ‘FORMS-G-ADMINSUPP-RESEARCH-REVISED’ and a Competition Title of ‘REVISED: Use for all R's and U's'.

The FORMS-G-ADMINSUPP-RESEARCH-REVISED application forms package must be used for any due dates on/after September 6, 2022.

Please be aware if you started the application process on the previously posted package, you will not be able to copy over your information to the new application forms package in this situation.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

The following section of PAR-22-114 has been changed:

Part 1. Overview Information, Key Dates

Currently, it reads:

Application Due Date(s)

September 06, 2022; January 23, 2023; September 06, 2023; January 23, 2024; September 06, 2024; January 23, 2025

Revised to read (in bold italics)

Application Due Date(s)

September 23, 2022; January 23, 2023; September 06, 2023; January 23, 2024; September 06, 2024; January 23, 2025

All other aspects of PAR-22-114 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Cancer Disparities Research

Maria Jamela R. Revilleza, PhD, MS
National Cancer Institute (NCI)
Telephone: 240-620-0616
Email: [email protected]

Population Sciences

Amy Kennedy, PhD, MPH
National Cancer Institute (NCI)
Telephone: 240-781-3335
Email: [email protected]

Translational and Clinical Studies

Minkyung (Min) H. Song, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6139
E-mail: [email protected]

Cancer Prevention

Vikrant Sahasrabuddhe, MBBS., MPH., DrPH
National Cancer Institute (NCI)
Telephone: 240-276-7332
Email: [email protected]

Basic Cancer Biology Research

Natalia Mercer, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6220
E-mail:  [email protected]

Global Health

James Alaro, PhD
National Cancer Institute (NCI)
Telephone: 2402766429
Email: james. [email protected]

Financial/Grants Management Contact(s)

Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: [email protected]